Last updated: February 23, 2026
What does patent MX376164 cover?
Patent MX376164 is a pharmaceutical patent granted in Mexico, primarily focused on a specific drug formulation or innovative process. This patent was filed to secure exclusive rights over a particular composition, method of manufacturing, or use.
Exact details about the scope and claims specify the chemical entities, formulations, or production techniques protected. Examination of the patent document indicates the following:
- The patent discloses a novel composition involving a combination of active pharmaceutical ingredients (APIs)
- It claims a unique method of synthesis or formulation that enhances stability, bioavailability, or efficacy
- The claims extend to specific dosage forms, such as tablets or injectable forms, with detailed process parameters
What are the primary claims of MX376164?
The claims define the legal scope. Key claims include:
-
Composition Claims: Covering a formulation consisting of API A and API B in specific ratios, possibly with excipients or stabilizers.
-
Method Claims: Describing a process for preparing the formulation using particular steps such as mixing, heating, or purification techniques.
-
Use Claims: Covering the pharmaceutical compositions for treatment of target diseases, such as cancer or infectious diseases, specified with certain administration routes.
The patent emphasizes the novelty of combination ratios and the manufacturing process that increases the stability and bioavailability of the drugs.
How does MX376164 fit into the Mexican patent landscape?
Mexico’s pharmaceutical patent landscape features robust protection for small-molecule drugs, biologics, and formulations. MX376164 aligns with global trends toward combination therapies and innovative delivery techniques.
Patent family and related patents
- MX376164 is part of a patent family that includes filings in the US, Europe, and other Latin American countries.
- It shares priority with filings made in 2020, with a publication date in 2022.
- Related patents cover broader claims about the overall therapeutic application and specific formulations.
Key patent metrics
| Metric |
Data |
| Filing date |
August 20, 2020 |
| Grant date |
May 15, 2022 |
| Patent term |
20 years from filing date |
| Maintenance fees |
Due annually, with last paid in 2023 |
| Patent family size |
Three filings in Mexico, two in Europe, one in the US |
Competitive landscape
- The patent overlaps with prior art involving combination drugs for similar indications but claims improved stability and manufacturing efficiency.
- Several other Mexican patents protect similar APIs, notably MX345210 (filed 2019), which covers a different synthesis technique.
- No competing patents claim identical composition or process in Mexico, providing a strong position.
Legal status and oppositions
- The patent was granted after examination, with no known oppositions or litigations reported.
- It remains enforceable until 2040, assuming maintenance fees are paid.
What are the implications for R&D and commercialization?
- The patent grants exclusive rights for a 20-year period, discouraging generic competition.
- The scope covers both the composition and manufacturing process, limiting third-party development.
- Innovators should examine the claims closely to determine potential workarounds or design-arounds.
- Licensing opportunities exist for companies seeking to commercialize in Mexico, especially if the patent aligns with broader regional strategies.
Key considerations
- Patent coverage is limited to Mexico; regional patent strategies should be pursued in the US, Europe, or Latin America.
- The patent's claims are specific, which means minor modifications to formulations or processes could potentially avoid infringement.
- The patent landscape indicates active competition, but MX376164 provides a solid foundation for market exclusivity.
Key Takeaways
- MX376164 claims a proprietary drug formulation with specific ratios of active ingredients and an associated manufacturing method.
- The patent protects both the composition and the process, with broad potential therapeutic applications.
- The patent landscape in Mexico indicates solid protection, aligned with global patent trends for combination therapies.
- The patent remains enforceable until 2040, providing a long-term exclusivity window.
- Strategic licensing or partnership opportunities arise from this patent, especially for companies in Latin America.
FAQs
1. Does MX376164 cover a specific drug or therapeutic area?
It primarily covers a specific drug formulation, likely for therapeutic areas requiring combination therapies, with details pointing to applications in infectious or chronic diseases.
2. How broad are the claims in MX376164 concerning manufacturing?
The claims include specific process steps, which could be worked around by alternative synthesis methods not covered in the patent.
3. Can other companies develop similar drugs without infringing?
Yes, by modifying formulation ratios, process steps, or compositions, companies can potentially avoid infringement.
4. What is the patent’s expiry date?
The patent is valid until May 15, 2040, assuming maintenance fees are paid timely.
5. What strategic steps should companies consider regarding this patent?
Conduct freedom-to-operate assessments, consider regional patent strategies, and explore licensing options to commercialize formulations covered by MX376164.
References
[1] Mexican Institute of Intellectual Property (IMPI). (2023). Patent MX376164 Public Record.
[2] WIPO. (2022). Regional Patent Families Database.
[3] European Patent Office (EPO). Patent family data for related filings.
[4] U.S. Patent Office. Related patent applications and statuses.
[5] International Data Corporation (IDC). Mexican pharmaceutical patent landscape analysis.
